Rubius Therapeutics (NASDAQ:RUBY) was downgraded by Zacks Investment Research from a "hold" rating to a "sell" rating in a research report issued to clients and investors on Saturday, Zacks.com reports.
According to Zacks, "Rubius Therapeutics, Inc. is a bio-technology company. It develops cellular therapies for the treatment of auto-immune, metabolic and other diseases. Rubius Therapeutics, Inc. is based in Cambridge, United States. "
RUBY has been the subject of a number of other research reports. SVB Leerink reaffirmed a "market perform" rating and set a $4.00 target price (down previously from $5.00) on shares of Rubius Therapeutics in a report on Tuesday. Morgan Stanley lifted their target price on Rubius Therapeutics from $5.00 to $10.00 and gave the company an "equal weight" rating in a report on Tuesday, January 19th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company. Rubius Therapeutics currently has a consensus rating of "Hold" and an average price target of $12.60.
Shares of RUBY opened at $10.38 on Friday. The business has a 50-day moving average of $11.37 and a 200 day moving average of $7.12. Rubius Therapeutics has a fifty-two week low of $3.35 and a fifty-two week high of $15.99. The firm has a market cap of $842.67 million, a P/E ratio of -4.85 and a beta of 2.37. The company has a debt-to-equity ratio of 0.43, a quick ratio of 7.15 and a current ratio of 7.15.
Rubius Therapeutics (NASDAQ:RUBY) last posted its earnings results on Tuesday, February 23rd. The company reported ($0.50) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.53) by $0.03. As a group, research analysts predict that Rubius Therapeutics will post -2.11 earnings per share for the current fiscal year.
In other news, Director David R. Epstein sold 7,404 shares of Rubius Therapeutics stock in a transaction dated Wednesday, February 10th. The stock was sold at an average price of $14.79, for a total transaction of $109,505.16. Following the completion of the sale, the director now owns 4,726,220 shares in the company, valued at approximately $69,900,793.80. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director David R. Epstein sold 89,233 shares of Rubius Therapeutics stock in a transaction dated Monday, February 8th. The shares were sold at an average price of $14.88, for a total value of $1,327,787.04. Following the sale, the director now owns 4,726,220 shares of the company's stock, valued at approximately $70,326,153.60. The disclosure for this sale can be found here. Company insiders own 58.40% of the company's stock.
A number of large investors have recently added to or reduced their stakes in RUBY. NEXT Financial Group Inc bought a new stake in Rubius Therapeutics in the 3rd quarter worth approximately $31,000. BNP Paribas Arbitrage SA lifted its position in Rubius Therapeutics by 271.1% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 9,646 shares of the company's stock worth $48,000 after buying an additional 7,047 shares during the last quarter. GSA Capital Partners LLP bought a new stake in Rubius Therapeutics in the 3rd quarter worth approximately $54,000. Citigroup Inc. lifted its position in Rubius Therapeutics by 42.7% in the 4th quarter. Citigroup Inc. now owns 10,953 shares of the company's stock worth $83,000 after buying an additional 3,278 shares during the last quarter. Finally, Dimensional Fund Advisors LP bought a new stake in Rubius Therapeutics in the 4th quarter worth approximately $95,000. Institutional investors own 93.74% of the company's stock.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes.
Recommended Story: Trading Halts
Get a free copy of the Zacks research report on Rubius Therapeutics (RUBY)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Analysts Hate These 12 Stocks
When a single Wall Street analyst downgrades one of your stocks, you might think they are just having a bad day or have an incorrect investment thesis. One downgrade typically won't have a significant impact on the price of one of your stocks, but what if analysts repeatedly downgraded a company over the last 30, 60, or 90 days? You would know something is seriously wrong.
Today, we invite you to take a free exclusive look at our up-to-the-minute list of 12 "Most Downgraded" stocks. These are true strong sell stocks. Analysts are abandoning them in droves and issuing rare downgrades and sell ratings. If any of these stocks are lurking around in your portfolio, seriously consider whether or not they still belong in your portfolio.
View the "Analysts Hate These 12 Stocks".